Leo Pharma and Astrazeneca keep future plans tight for tralokinumab
![Jörg Möller, head of global research and development at Leo Pharma, doesn't have a lot to say when it comes to Leo Pharma's hopes for tralokinumab besides atopic eczema](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13606039.ece/ALTERNATES/schema-16_9/Leo%2520Pharma%2520jorg%2520muller.jpg)
The US approval of Leo Pharma's eczema drug, tralokinumab, has been a popular topic at the Danish dermatology firm, which has clear blockbuster expectations for the treatment.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.